Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus

Accapezzato, Daniele; Caccavale, Rosalba; Paroli, Maria Pia; Gioia, Chiara; Nguyen, Bich Lien; Spadea, Luca; Paroli, Marino

doi:10.3390/ijms24076578

Cited by 29 publications

(17 citation statements)

References 212 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SLE stands as a quintessential autoimmune disorder with the capacity to exert its influence over a myriad of bodily tissues and organs. The hallmark of systemic lupus erythematosus is an exuberant activation of the immune system, culminating in the escalation of autoantibodies and immune complexes, which, in turn, contribute to organ dysfunction [23,24] . Using the currently popular single-cell sequencing technology, we integrated multiple scRNA-seq datasets [25,26] .…”

Section: Discussionmentioning

confidence: 99%

Revealing the Immune Heterogeneity in Systemic Lupus Erythematosus Based on Multi-Omics Data Analysis

Liu,

Gong,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Systemic lupus erythematosus is an autoimmune disorder characterized by a spectrum of clinical manifestations. With the progress of next-generation sequencing (NGS) technology, novel techniques for sequencing T cell receptors and B cell receptors have emerged. In this study, we employed the computational approach TRUST4 to construct TCR and BCR libraries using a substantial volume of RNA-seq data extracted from the peripheral blood of sepsis patients. Subsequently, we conducted an analysis to assess the clonality and diversity of the immune repertoire associated with this disease. A total of 30 distinct cell types were annotated and subsequently categorized into 12 clusters. SLE group demonstrated an increase in the innate immune responses of CD14 monocytes, CD16 monocytes, Megakaryocytes, NK cells, and Neutrophis in comparison to the HC group. The CellChat analysis findings unveiled four distinct patterns for input signals and four patterns for output signals. The results of trajectory analysis revealed that the majority of cell subsets are positioned in a single developmental stage. Our research results comprehensively demonstrate the dynamic changes of immune cells during the onset of SLE, and identify specific V and J genes in TCR and BCR that can be used to expand our understanding of SLE.

show abstract

Section: Discussionmentioning

confidence: 99%

Revealing the Immune Heterogeneity in Systemic Lupus Erythematosus Based on Multi-Omics Data Analysis

Liu,

Gong,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Other treatments, well documented in SLE (e.g., belimumab, an anti-BAFF human monoclonal antibody, anifrolumab, a monoclonal antibody against type I interferon receptor subunit 1, etc.) could also present potential therapeutic options in SLE-associated CAPS [ 84 ]. However, the efficacy and safety profiles of these drugs have never been evaluated in this population.…”

Section: Therapeutic Management Of Capsmentioning

confidence: 99%

Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria

Jacobs,

Wauters,

Lablad

et al. 2024

Antibodies

View full text Add to dashboard Cite

Catastrophic antiphospholipid syndrome (CAPS) is a rare and life-threatening condition characterized by the persistence of antiphospholipid antibodies and occurrence of multiple vascular occlusive events. CAPS currently remains a diagnostic challenge and requires urgent treatment. The diagnosis of CAPS is made difficult by classification criteria used as diagnostic criteria in clinical practice, knowledge derived from retrospective data and case reports, confounding clinical and biological features, and its rapid onset and mortality. The absence of prospective studies of CAPS limits the strength of evidence for guideline treatment protocols. This comprehensive review summarizes the current understanding of the disease, and discusses how the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria impact the definition and therapeutic management of CAPS, which is considered the most severe form of APS. The correct integration of 2023 ACR/EULAR APS classification criteria is poised to facilitate CAPS diagnosis, particularly in critical situations, offering a promising avenue for improved outcomes.

show abstract

“…Type I interferon (IFN) (IFNα), produced mainly by plasmacytoid dendritic cells (pDCs), has also been shown to play an important role in the pathogenesis of SLE [30]. IFNα activity is known to be mediated by TLR7 and TLR9 expressed by pDCs [31]. Through this signaling pathway, secreted IFNα activates the transcription of hundreds of different genes involved in autoimmunity [32,33].…”

Section: Systemic Lupus Erythematosus (Sle)mentioning

confidence: 99%

Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies

Chasov,

Zmievskaya,

Ganeeva

et al. 2024

Antibodies

View full text Add to dashboard Cite

Systemic autoimmune diseases (SAIDs), such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and rheumatoid arthritis (RA), are fully related to the unregulated innate and adaptive immune systems involved in their pathogenesis. They have similar pathogenic characteristics, including the interferon signature, loss of tolerance to self-nuclear antigens, and enhanced tissue damage like necrosis and fibrosis. Glucocorticoids and immunosuppressants, which have limited specificity and are prone to tolerance, are used as the first-line therapy. A plethora of novel immunotherapies have been developed, including monoclonal and bispecific antibodies, and other biological agents to target cellular and soluble factors involved in disease pathogenesis, such as B cells, co-stimulatory molecules, cytokines or their receptors, and signaling molecules. Many of these have shown encouraging results in clinical trials. CAR-T cell therapy is considered the most promising technique for curing autoimmune diseases, with recent successes in the treatment of SLE and SSc. Here, we overview novel therapeutic approaches based on CAR-T cells and antibodies for targeting systemic autoimmune diseases.

show abstract

Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus

Cited by 29 publications

References 212 publications

Revealing the Immune Heterogeneity in Systemic Lupus Erythematosus Based on Multi-Omics Data Analysis

Revealing the Immune Heterogeneity in Systemic Lupus Erythematosus Based on Multi-Omics Data Analysis

Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria

Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies

Contact Info

Product

Resources

About